Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease

Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease

We developed an endophenotype disease module-based methodology for Alzheimer's disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier. Based on retrospective case-control pharmacoepidemiologic analyses of insurance claims data for 7.23 million individuals,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature aging 2021-12, Vol.1 (12), p.1175-1188
Hauptverfasser: Fang, Jiansong, Zhang, Pengyue, Zhou, Yadi, Chiang, Chien-Wei, Tan, Juan, Hou, Yuan, Stauffer, Shaun, Li, Lang, Pieper, Andrew A, Cummings, Jeffrey, Cheng, Feixiong
Format: Artikel
Sprache:eng
Schlagworte:
Alzheimer Disease - drug therapy
Data Mining
Disease
Drug development
Endophenotypes
FDA approval
Genomics
Humans
Hypotheses
Hypothesis testing
Insurance claims
Medicine
Pathology
Patients
Proteins
Proteomics
R&D
Research & development
Retrospective Studies
Sildenafil Citrate - pharmacology
Stem cells
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We developed an endophenotype disease module-based methodology for Alzheimer's disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier. Based on retrospective case-control pharmacoepidemiologic analyses of insurance claims data for 7.23 million individuals, we found that sildenafil usage was significantly associated with a 69% reduced risk of AD (hazard ratio = 0.31, 95% confidence interval 0.25-0.39, P
ISSN:2662-8465
2662-8465
DOI:10.1038/s43587-021-00138-z